OMAHA, Neb., April 14, 2011 /PRNewswire/ -- Transgenomic, Inc. (OTC/BB: TBIO) announced today that it has launched kits for high sensitivity mutational analysis of the BRAF and PIK3CA genes. These new ...
Assures 100x upgraded detection sensitivity compare to ddPCR Higher the possibility of precision medicine in the 1st and 2nd stages of cancer patients SEOUL, South Korea--(BUSINESS WIRE)--GENECAST, ...
Testing for breast cancer and other diseases caused by BRCA1 and BRCA2 genetic mutations becomes easier now that the U.S. Federal Drug Administration has approved 23andMe's genetic test. The test kit ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results